Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for C4 Therapeutics, Inc. (CCCC : NSDQ)

• Company Description    C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. C4 Therapeutics Inc. is based in WATERTOWN, Mass. Number of Employees: 104

• Price / Volume Information    Yesterday's Closing Price: $3.56 Daily Weekly Monthly 20 Day Moving Average: 2,886,775 shares Shares Outstanding: 110.57 (millions) Market Capitalization: $393.62 (millions) Beta: 2.77 52 Week High: $3.95 52 Week Low: $1.21 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 19.87% 14.01% 12 Week 28.06% 18.38% Year To Date 86.39% 69.44%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 490 Arsenal Way Suite 120 - Watertown,MA 02472 USA ph: 617-231-0700 fax: - csolberg@c4therapeutics.com http://www.c4therapeutics.com

• General Corporate Information    Officers Andrew J. Hirsch - President and Chief Executive Officer Ronald Cooper - Chairman Kendra R. Adams - Chief Financial Officer and Treasurer Kenneth C. Anderson - Director Laura Bessen - Director Peer Information C4 Therapeutics, Inc. (CORR.) C4 Therapeutics, Inc. (RSPI) C4 Therapeutics, Inc. (CGXP) C4 Therapeutics, Inc. (BGEN) C4 Therapeutics, Inc. (GTBP) C4 Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 12529R107 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 110.57 Most Recent Split Date: (:1) Beta: 2.77 Market Capitalization: $393.62 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.87 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.68 Price/Cash Flow: - Price / Sales: 11.29 EPS Growth vs. Year Ago Period: 45.95% vs. Previous Quarter: -11.11% Sales Growth vs. Year Ago Period: -15.00% vs. Previous Quarter: -44.15% ROE 03/31/26 - -50.68 12/31/25 - -53.83 09/30/25 - -64.40 ROA 03/31/26 - -33.22 12/31/25 - -33.85 09/30/25 - -38.69 Current Ratio 03/31/26 - 9.00 12/31/25 - 7.81 09/30/25 - 5.76 Quick Ratio 03/31/26 - 9.00 12/31/25 - 7.81 09/30/25 - 5.76 Operating Margin 03/31/26 - -297.76 12/31/25 - -292.08 09/30/25 - -395.51 Net Margin 03/31/26 - -297.76 12/31/25 - -292.08 09/30/25 - -395.51 Pre-Tax Margin 03/31/26 - -297.41 12/31/25 - -291.74 09/30/25 - -395.08 Book Value 03/31/26 - 2.12 12/31/25 - 2.65 09/30/25 - 1.59 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©